99mTc-EDDA/HYNIC-octreotate scintigraphy, an efficient method for the detection and staging of carcinoid tumours: results of 3 years’ experience
- 24 May 2006
- journal article
- research article
- Published by Springer Science and Business Media LLC in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 33 (10), 1123-1133
- https://doi.org/10.1007/s00259-006-0113-7
Abstract
At all stages of the disease, serious difficulties are encountered in the imaging diagnosis of carcinoids. Somatostatin receptor scintigraphy (SRS) holds great promise for detecting primary tumours and metastases. 99mTc-EDDA/HYNIC-octreotate should significantly improve the diagnosis of carcinoids in comparison with 111In-Octreoscan owing to the better affinity for SSR2 and the higher count rate. The aim of this study was to assess the diagnostic efficiency of 99mTc-EDDA/HYNIC-octreotate scintigraphy in the detection and staging of carcinoid tumours. The study population comprised 75 patients (age 48.5±15.5 years): 46 with histological confirmation of carcinoid and 29 with suspected disease. 99mTc-EDDA/HYNIC-octreotate (740 MBq) SRS and CT were performed in all patients. Fifteen patients were examined with 111In-Octreoscan. High-quality 99mTc-EDDA/HYNIC-octreotate images were obtained in all cases, with maximum tumour tracer accumulation 4 h p.i. The mean target/non-target ratios for whole body (WB) and SPECT scans were, respectively, as follows: primary lesions: 4.5 and 10.2; metastases: liver, 3.1 and 12.3; abdominal focal lesions, 2.7 and 5.8; lung, 2.7 and 8.3; mediastinum, 3.4 and 7.6; bones, 6.8 and 19.0. 99mTc-EDDA/HYNIC-octreotate WB scans revealed more metastases than 111In-Octreoscan, with better individual separation. 99mTc-EDDA/HYNIC-octreotate SRS revealed new metastatic lesions in seven patients with confirmed carcinoid, and in four with dissemination the primary focus was found. Five patients qualified for radioguided surgery and 11 were referred to 90Y-DOTA-TATE therapy. The sensitivity of SRS in comparison with CT was higher for primary lesions and liver and abdominal lymph node metastases. In the subgroup of patients with suspected neuroendocrine tumours, two duodenal carcinoids, one thymic carcinoid and one ileal carcinoid were found. 99mTc-EDDA/HYNIC-octreotate, with high imaging quality, is an excellent alternative to 111In-Octreoscan for staging of carcinoids, and it seems to be the method of choice for detection of the primary focus in patients with metastases from an unknown primary tumour.Keywords
This publication has 32 references indexed in Scilit:
- Nuclear medicine in the detection, staging and treatment of gastrointestinal carcinoid tumoursBest Practice & Research Clinical Endocrinology & Metabolism, 2005
- Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumoursGut, 2005
- Early‐stage carcinoids of the gastrointestinal tractCancer, 2005
- Metastatic Carcinoid Tumors: A Clinical ReviewThe Oncologist, 2005
- 99mTc-Demotate 1: first data in tumour patients?results of a pilot/phase I studyEuropean Journal of Nuclear Medicine and Molecular Imaging, 2003
- Clinical usefulness of 99m Tc-EDDA/HYNIC-TOC scintigraphy in oncological diagnostics: a preliminary communicationEuropean Journal of Nuclear Medicine and Molecular Imaging, 2003
- Somatostatin and Its Receptor FamilyFrontiers in Neuroendocrinology, 1999
- 99mTc Labeling of Highly Potent Small PeptidesBioconjugate Chemistry, 1997
- Somatostatin receptor scintigraphy with [111In-DTPA-d-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patientsEuropean Journal of Nuclear Medicine and Molecular Imaging, 1993
- Somatostatin analogue scintigraphy in carcinoid tumoursEuropean Journal of Nuclear Medicine and Molecular Imaging, 1993